

WHAT IS CLAIMED IS:

- sub A17
1. A pharmaceutical composition for the treatment of sinusitis comprising a therapeutically effective amount of a peptide having a C-terminal sequence amino acid sequence KPV in combination with a therapeutically effective amount of a decongestant/antihistamine.
  - 5 2. The pharmaceutical composition of claim 1 wherein the peptide is selected from the group of peptides with a C-terminal amino acid sequence consisting of: KPV, VPK-Ac-CC-Ac-KPV, HFRWGKPV and SYSMEHFRWGKPV.
  3. The composition of claim 1 wherein said decongestant/antihistamine is selected from the group consisting of: pseudoephedrine, phenylephrine, phenylpropanolamine, chlorpheniramine, brompheniramine, pheniramine and loratidine.
  4. The composition of claim 1 further comprising a therapeutically effective amount of an antibiotic.
  5. The composition of claim 4 wherein said antibiotic is selected from the group consisting of: amoxicillin, ampicillin, azithromycin, erythromycin, nafcillin, penicillin, amoxicillin/clavulanate potassium, cefuroxime axetil, cefpodoxime proxetil, clarithromycin, and azithromycin.
  6. The composition of claim 1 further comprising a therapeutically effective amount of a glucocorticosteroid.
  7. The composition of claim 6 wherein said glucocorticosteroid is selected from the group consisting of: betamethasone, budesonide, cortisone, dexamethasone, hydrocortisone, methylprednisone, prednisone, triamcinolone.
  - 20 8. The composition of claim 1 further comprising a therapeutically effective amount of a fungicide.

**BEST AVAILABLE COPY**

1015055-121001

9. The composition of claim 8 wherein said fungicide is selected from the group consisting of: itraconazole, econazole, ketoconazole, miconazole and fluconazole.
10. The pharmaceutical composition of claim 1 further contained in a carrier.
11. The composition of claim 10 wherein the concentration of said peptide is at least  $10^{-12}$ M.
- 5 12. The composition of claim 11 wherein the carrier is selected from the group consisting of: saline, phosphate buffered saline, gelatin maltodextrin, cellulose, microcrystalline cellulose, methyl cellulose, carboxymethyl cellulose and hydroxymethyl cellulose with glycerin.
13. A pharmaceutical composition for the treatment of sinusitis comprising a therapeutically effective amount of a peptide having a C-terminal sequence amino acid sequence KPV in combination with a therapeutically effective amount of a decongestant/antihistamine and a therapeutically effective amount of a fungicide.
14. The pharmaceutical composition of claim 13 wherein the peptide is selected from the group of peptides with a C-terminal amino acid sequence consisting of: KPV, VPK-Ac-CC-Ac-KPV, HFRWGKPV and SYSMEHFRWGKPV.
15. The composition of claim 13 wherein said fungicide is selected from the group consisting of: itraconazole, econazole, ketoconazole, miconazole and fluconazole.
16. The composition of claim 13 further comprising application of a therapeutically effective amount of an antibiotic.
- 20 17. The composition of claim 16 wherein said antibiotic is selected from the group consisting of: amoxicillin, ampicillin, azithromycin, erythromycin, nafcillin, penicillin, amoxicillin/clavulanate potassium, cefuroxime axetil, cefpodoxime proxetil, clarithromycin, and azithromycin.

**BEST AVAILABLE COPY**

18. The composition of claim 13 further comprising a therapeutically effective amount of a glucocorticosteroid.
19. The composition of claim 18 wherein said glucocorticosteroid is selected from the group consisting of: betamethasone, cortisone, dexamethasone, hydrocortisone, methylprednisone, prednisone, triamcinolone.
20. The composition of claim 13 wherein said antihistamine/decongestant is selected from the group consisting of: pseudoephedrine, phenylephrine, phenylpropanolamine, chlorpheniramine, brompheniramine, pheniramine and loratidine.
21. The pharmaceutical composition of claim 10 further solvated in a carrier.
22. The composition of claim 21 wherein the concentration of said peptide is at least  $10^{-12}$ M.
23. The composition of claim 21 wherein the carrier is selected from the group consisting of: saline, phosphate buffered saline, gelatin maltodextrin, cellulose, microcrystalline cellulose, methyl cellulose, carboxymethyl cellulose and hydroxymethyl cellulose with glycerin.
24. A method for the treatment of sinusitis comprising application of a pharmaceutical effective amount of a peptide having a C-terminal sequence amino acid sequence KPV.
25. The method of claim 24 wherein the peptide is selected from the group with a C-terminal amino acid sequence consisting of KPV, VPK-Ac-CC-Ac-KPV, HFRWGKPV and SYSMEHFRWGKPV.
26. The method of claim 24 further comprising application of therapeutically effective amount of a fungicide.
27. The method of claim 26 wherein said fungicide is selected consisting of: itraconazole, econazole, ketoconazole, miconazole and fluconazole.

**BEST AVAILABLE COPY**

28. The method of claim 24 further comprising application of a therapeutically effective amount of an antibiotic.
29. The method of claim 28 wherein said antibiotic is selected from the group consisting of: amoxicillin, ampicillin, azithromycin, erythromycin, nafcillin, penicillin, amoxicillin/clavulanate potassium, cefuroxime axetil, cefpodoxime proxetil, clarithromycin, and azithromycin.
30. The method of claim 24 further comprising application of a therapeutically effective amount of a decongestant/antihistamine.
31. The method of claim 28 further said decongestant is selected from the group consisting of: pseudoephedrine, phenylephrine, phenylpropanolamine, chlorpheniramine, brompheniramine, pheniramine and loratidine.
32. The method of claim 24 further comprising application of a therapeutically effective amount of a glucocorticosteroid.
33. The method of claim 32 wherein said glucocorticosteroid is selected from the group consisting of: betamethasone, cortisone, dexamethasone, hydrocortisone, methylprednisone, prednisone, triamcinolone.
34. The method of claim 24 wherein said peptide is systemically or topically applied before, during or after surgery performed to treat sinusitis.

**BEST AVAILABLE COPY**